Stockscreener 앱 받기
68.25
0.70%
-0.48
시간 외 거래:
67.75
-0.50
-0.73%
Biomarin Pharmaceutical Inc 주식(BMRN)의 최신 뉴스
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Up on Strong Earnings - MarketBeat
Cantor Fitzgerald Reiterates Overweight Rating for BioMarin Pharmaceutical (NASDAQ:BMRN) - MarketBeat
UBS Group Boosts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $113.00 - MarketBeat
Piper Sandler Raises BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $126.00 - MarketBeat
BioMarin to Report Q4 Earnings: Here's What to Expect - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $103.00 at Bank of America - MarketBeat
BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Simply Wall St
Zacks Research Issues Positive Estimate for BMRN Earnings - MarketBeat
Pfizer stops commercialization of hemophilia gene therapy Beqvez - Reuters
58,400 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Purchased by Alberta Investment Management Corp - MarketBeat
Cantor Fitzgerald maintains BioMarin stock with $90 target By Investing.com - Investing.com South Africa
BioMarin’s Earnings Call Highlights Strong Growth and Optimism - TipRanks
BioMarin’s Voxzogo Expected To Benefit From ‘Sticky’ Nature Of Achondroplasia Market - Scrip
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today - Yahoo
BioMarin Pharmaceutical (NASDAQ:BMRN) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Releases FY 2025 Earnings Guidance - MarketBeat
Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews - Benzinga
BioMarin Earnings: Sales Driven by Strong Uptake of Voxzogo and Enzyme Therapies; Shares Undervalued - Morningstar
BioMarin's Narrow Moat Supported by Rare Disease Therapies and Developing Pipeline - Morningstar
Cantor Fitzgerald maintains BioMarin stock with $90 target - Investing.com
UBS Adjusts Price Target on BioMarin Pharmaceutical to $113 From $109, Maintains Buy Rating - Marketscreener.com
Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View - Yahoo Finance
BMO maintains $115 target on BioMarin stock, cites growth potential - Investing.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2024 Earnings Call Transcript - MSN
Piper Sandler lifts BioMarin stock target to $126, maintains Overweight - Investing.com
Zacks Research Analysts Boost Earnings Estimates for BMRN - MarketBeat
Roku, BioMarin, Amplitude - TradingView
BioMarin projects 10% revenue growth to $3.1B-$3.2B for 2025, driven by VOXZOGO expansion - MSN
BioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on Thursday - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by New York State Teachers Retirement System - MarketBeat
BioMarin’s Record Growth and 2025 Outlook - TipRanks
After-hours movers: Carvana, Klaviyo, NerdWallet, BioMarin Pharma, and more - Investing.com
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
BioMarin Pharmaceutical (BMRN) Surpasses Q4 Earnings and Revenue Estimates - Nasdaq
BioMarin: EPS Surges Past Expectations - The Motley Fool
BioMarin Pharma Expects Double-Digit Revenue And Profitability Growth In 2025 - Nasdaq
BioMarin: Q4 Earnings Snapshot - The Bakersfield Californian
BioMarin Pharmaceutical Q4 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Set -- Shares Up After Hours - Marketscreener.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars - Financial Content
BioMarin Pharmaceutical Inc. Reports Fourth Quarter and Full Year 2024 Results - TradingView
Biomarin Pharma earnings beat by $0.37, revenue topped estimates - Investing.com Canada
Earnings Flash (BMRN) Biomarin Pharmaceutical Posts Q4 Revenue $747M, vs. FactSet Est of $712.3M - Marketscreener.com
Biomarin Pharmaceutical Inc. Q4 Profit Increases, Beats Estimates - Nasdaq
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Cut by Van ECK Associates Corp - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Rhumbline Advisers Buys 11,025 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings - The Globe and Mail
Savant Capital LLC Acquires 14,930 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast? - Yahoo Finance
Entropy Technologies LP Acquires Shares of 7,604 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $30.90 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded by StockNews.com to "Strong-Buy" Rating - MarketBeat
5,014 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Bleakley Financial Group LLC - MarketBeat
0.27%
3.05%
자본화:
|
볼륨(24시간):